全文获取类型
收费全文 | 810篇 |
免费 | 0篇 |
国内免费 | 2篇 |
专业分类
综合类 | 2篇 |
化学工业 | 9篇 |
金属工艺 | 4篇 |
无线电 | 1篇 |
一般工业技术 | 1篇 |
冶金工业 | 793篇 |
自动化技术 | 2篇 |
出版年
2012年 | 1篇 |
2010年 | 1篇 |
2007年 | 1篇 |
2005年 | 1篇 |
2004年 | 1篇 |
2003年 | 2篇 |
2002年 | 6篇 |
2001年 | 3篇 |
2000年 | 2篇 |
1999年 | 22篇 |
1998年 | 266篇 |
1997年 | 157篇 |
1996年 | 86篇 |
1995年 | 46篇 |
1994年 | 35篇 |
1993年 | 50篇 |
1992年 | 3篇 |
1991年 | 6篇 |
1990年 | 4篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 6篇 |
1980年 | 4篇 |
1978年 | 1篇 |
1977年 | 30篇 |
1976年 | 54篇 |
排序方式: 共有812条查询结果,搜索用时 15 毫秒
811.
RL Basser LB To CG Begley CA Juttner DW Maher J Szer J Cebon JP Collins I Russell I Olver 《Canadian Metallurgical Quarterly》1995,1(7):715-721
Women with primary breast cancer associated with extensive axillary node involvement or large primary tumors have a very poor prognosis despite treatment with standard-dose adjuvant chemotherapy. In an attempt to improve the outlook of these patients, we investigated the safety and feasibility of delivering three cycles of high-dose epirubicin and cyclophosphamide supported with filgrastim-mobilized peripheral blood progenitor cells (PBPC). Fifteen previously untreated women, median age 50 (range, 30-58) years, with poor prognosis early stage breast cancer received filgrastim (12 microgram/kg daily for 6 days) prior to chemotherapy to mobilize progenitor cells. Patients were then given three cycles of epirubicin (200 mg/m2) and cyclophosphamide (4 g/m2) at planned 28-day intervals, each followed by infusion of one third of the PBPC collected and daily administration of filgrastim (5 microgram/kg s.c.). Three leukaphereses collected a median of 114.9 (range, 22.7-273.5) x 10(4) granulocyte-macrophage-colony-forming cells/kg body weight. Hemopoietic recovery was rapid after each cycle, and there was no correlation between the rate of recovery and the number of granulocyte-macrophage-colony-forming cells infused. There was a small but significant progressive delay in recovery from hematological and nonhematological toxicities across the three cycles. Left ventricular ejection fraction fell to below 50% in eight (53%) patients, but none developed congestive cardiac failure. Two patients did not complete three cycles because of insufficient PBPC for a third cycle (n = 1) and 2-mercaptoethane sodium sulfonate- related drug reaction during the second cycle (n = 1). There were no deaths during the study or during the follow-up period (median, 70 weeks; range, 50-85 weeks), and no late toxicities occurred. Therefore, we concluded that the delivery of multiple cycles of nonmyeloablative, dose-intensive chemotherapy supported by PBPC and filgrastim is safe, and may be widely applicable to a variety of common chemosensitive cancers with a poor prognosis. The efficacy of three cycles of high-dose epirubicin and cyclophosphamide is to be compared with standard-dose chemotherapy in a randomized trial in patients with high-risk, operable stage II and III breast cancer. 相似文献
812.